The global medtech industry has a new leader, after a bulked-up Medtronic bumped Johnson & Johnson from first place. But astute M&A deals, as well as divestments and impact from poor sales and negative currency effects, have also led to other movements in the medtech rankings, according to Medtech Insight's annual review at the top medical device companies.
It took some time, but more than a year after Medtronic PLC completed its historic $43 billion merger with Covidien, the medtech giant has finally made it to the top of the leaderboard, a position long-occupied by Johnson & Johnson.
The 2016 edition of the MTI 100 – Medtech Insight's roll call of the top 100 companies ranked according to their medical device- and diagnostics-related sales for their most recent...
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
